CA3177118A1 - Methods for analysis of cell-free rna - Google Patents

Methods for analysis of cell-free rna Download PDF

Info

Publication number
CA3177118A1
CA3177118A1 CA3177118A CA3177118A CA3177118A1 CA 3177118 A1 CA3177118 A1 CA 3177118A1 CA 3177118 A CA3177118 A CA 3177118A CA 3177118 A CA3177118 A CA 3177118A CA 3177118 A1 CA3177118 A1 CA 3177118A1
Authority
CA
Canada
Prior art keywords
cancer
molecules
genes
target
cfrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177118A
Other languages
English (en)
French (fr)
Inventor
Ruth E. MAUNTZ
Matthew Larson
Archana Shenoy
Arash Jamshidi
David BURKHARDT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grail Inc
Original Assignee
Grail Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grail Inc filed Critical Grail Inc
Publication of CA3177118A1 publication Critical patent/CA3177118A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Microbiology (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3177118A 2020-06-16 2021-06-16 Methods for analysis of cell-free rna Pending CA3177118A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039886P 2020-06-16 2020-06-16
US63/039,886 2020-06-16
PCT/US2021/037668 WO2021257729A2 (en) 2020-06-16 2021-06-16 Methods for analysis of cell-free rna

Publications (1)

Publication Number Publication Date
CA3177118A1 true CA3177118A1 (en) 2021-12-23

Family

ID=78824561

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177118A Pending CA3177118A1 (en) 2020-06-16 2021-06-16 Methods for analysis of cell-free rna

Country Status (7)

Country Link
US (1) US20210388451A1 (enExample)
EP (1) EP4165206A4 (enExample)
JP (1) JP2023534094A (enExample)
CN (1) CN115698321A (enExample)
AU (1) AU2021292521A1 (enExample)
CA (1) CA3177118A1 (enExample)
WO (1) WO2021257729A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024535694A (ja) * 2021-09-10 2024-10-02 グレイル インコーポレイテッド 生体液中の標的分子の分析方法
WO2023147445A2 (en) * 2022-01-27 2023-08-03 Oregon Health & Science University Cell-free rna biomarkers for the detection of cancer or predisposition to cancer
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
CN116312800A (zh) * 2023-03-08 2023-06-23 中山大学附属第八医院（深圳福田） 一种基于血浆中循环rna全转录组测序的肺癌特征识别方法、装置和存储介质
WO2024263972A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating uncommon cancers
CN116825177A (zh) * 2023-06-28 2023-09-29 北京津渡生科科技有限公司 基于统计学与随机森林的游离rna肝癌早筛方法及系统
CN120752533A (zh) * 2023-09-18 2025-10-03 深圳华大生命科学研究院 对游离rna进行组织溯源的方法及装置
WO2026094720A1 (ja) * 2024-10-28 2026-05-07 アークレイ株式会社 性質判定モデルの生成方法、性質判定モデル、性質判定方法、性質判定装置、プログラム及び記録媒体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150160221A1 (en) * 2012-01-09 2015-06-11 Suzhou Microdiag Biomedicine Co., Ltd Biomarkers for breast cancer predictions and diagnoses
WO2016077709A1 (en) * 2014-11-14 2016-05-19 Liquid Genomics, Inc. Use of circulating cell-free rna for diagnosis and/or monitoring cancer
JP2020511933A (ja) * 2016-11-22 2020-04-23 プライム ゲノミクス，インク． 癌検出のための方法
WO2018208892A1 (en) * 2017-05-10 2018-11-15 Nantomics, Llc Circulating rna for detection, prediction, and monitoring of cancer
CA3095056A1 (en) * 2018-04-13 2019-10-17 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay of biological samples
DK3781714T3 (da) * 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
EP4647512A2 (en) * 2018-06-22 2025-11-12 ClearNote Health, Inc. Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use
US20200105375A1 (en) * 2018-09-28 2020-04-02 Grail, Inc. Models for targeted sequencing of rna
US11512349B2 (en) * 2018-12-18 2022-11-29 Grail, Llc Methods for detecting disease using analysis of RNA

Also Published As

Publication number Publication date
US20210388451A1 (en) 2021-12-16
CN115698321A (zh) 2023-02-03
EP4165206A2 (en) 2023-04-19
WO2021257729A3 (en) 2022-03-03
WO2021257729A2 (en) 2021-12-23
AU2021292521A1 (en) 2022-12-08
EP4165206A4 (en) 2024-07-17
JP2023534094A (ja) 2023-08-08

Similar Documents

Publication Publication Date Title
US20210388451A1 (en) Methods for analysis of cell-free rna
US9128096B2 (en) Methods for determining cancer resistance to histone deacetylase inhibitors
US20230086722A1 (en) Methods for analysis of target molecules in biological fluids
CA3121923A1 (en) Methods for detecting disease using analysis of rna
US20250201370A1 (en) Methods of treating breast cancer
US20250101524A1 (en) Compositions and methods for cell-free dna epigenetic gastrointestinal cancer detection and treatment
WO2017087947A2 (en) Method of treatment of follicular lymphoma with a btk inhibitor
US12385920B2 (en) IL-6 signaling and breast cancer
US20240271221A1 (en) Methods for analysis of cell-free nucleic acids in urine
HK40087073A (zh) 用於血浆游离rna分析的多种方法
WO2022246002A2 (en) Methods and compositions for determining cancer risk
US20260103758A1 (en) Methods and biomarkers for treating breast cancer
WO2022246000A1 (en) Compositions and methods for determining dna methylation level in cancer
HK40108998A (zh) 用於无细胞的dna表观遗传的胃肠道癌检测以及治疗的组成物和方法
US20230175072A1 (en) 3 flap okazaki fragments and uses thereof
WO2022235701A1 (en) Gene expression profiling methods and compositions for determining cancer and treatment thereof

Legal Events

Date Code Title Description
U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204